Patent classifications
A61P11/16
Porcine G-CSF variants and their uses
The present invention relates to variants of porcine granulocyte colony stimulating factor (pG-CSF). The pG-CSF variants are useful in treating preventing or reducing the incidence of bacterial infections in swine. Methods of treating swine are disclosed.
Crude drug composition for preventing or treating respiratory diseases
The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising as an active ingredient two or more mixed extracts selected from the group consisting of a Brassicae Semen extract, an Adenophorae Radix extract, a Lonicerae Folium extract and a Perillae Semen extract. A composition comprising mixed extracts of Brassicae Semen, Adenophorae Radix, Lonicerae Folium and Perillae Semen of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue, inhibits aging action and inflammation induced by inflammation-inducing substances such as fine dust, and has an excellent antioxidant effect. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere.
Crude drug composition for preventing or treating respiratory diseases
The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising as an active ingredient two or more mixed extracts selected from the group consisting of a Brassicae Semen extract, an Adenophorae Radix extract, a Lonicerae Folium extract and a Perillae Semen extract. A composition comprising mixed extracts of Brassicae Semen, Adenophorae Radix, Lonicerae Folium and Perillae Semen of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue, inhibits aging action and inflammation induced by inflammation-inducing substances such as fine dust, and has an excellent antioxidant effect. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere.
Promotion of epithelial repair
There is provided a method for promoting epithelium repair in a subject, the method comprising administering to the subject a therapeutically effective amount of an activator of PI3K/Akt signalling.
Promotion of epithelial repair
There is provided a method for promoting epithelium repair in a subject, the method comprising administering to the subject a therapeutically effective amount of an activator of PI3K/Akt signalling.
Modified bovine G-CSF polypeptides and their uses
Modified bovine G-CSF polypeptides and uses thereof are provided.
Dihydropyrrolopyridine inhibitors of ROR-gamma
Provided are novel compounds of Formula (I): ##STR00001##
pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
Imidazo[4,5-C]pyridine derived SSAO inhibitors
A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R.sup.1, W, V, and R.sup.3 are as defined in claim 1. ##STR00001##
Substituted imidazo[4,5-c]pyridine compounds and compositions thereof
Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: ##STR00001##
where V, W, X, Y, Z, R.sup.1, and R.sup.3 are as defined herein.
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.